GlassScriptPhysician profile
Sean C Rice
NPI 1447679584
$2,439.39
in general payments reported to CMS, 2019-2025
25 companies · $786 in 2025
The $786 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.55 · 2022: $475 · 2023: $746 · 2024: $418 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.87 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.53 | 2022-2025 | |
| Merz North America, INC. | $199.74 | 2025 | |
| Gilead Sciences, INC. | $146.93 | 2022-2023 | |
| 3-D Matrix, INC. | $124.78 | 2024 | |
| Lilly USA, LLC | $123.59 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $104.65 | 2022-2023 | Dificid |
| Janssen Scientific Affairs, LLC | $99.16 | 2023 | Stelara |
| Janssen Biotech, INC. | $98.54 | 2022-2025 | Tremfya |
| Celgene Corporation | $97.84 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $97.37 | 2023 | Dupixent |
| Boston Scientific Corporation | $89.24 | 2023-2025 | Axios, Compliance Endokit, Interject |
| E.R. Squibb & Sons, L.L.C. | $87.78 | 2023 | |
| Daiichi Sankyo INC. | $72.06 | 2023-2024 | Injectafer |
| Merit Medical Systems INC | $67.55 | 2025 | Endomaxx Stent and Delivery System, Esophyx |
| Medtronic, INC. | $67.55 | 2025 | Endoflip |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $45.51 | 2022 | |
| Endogastric Solutions, INC | $29.16 | 2022-2023 | Esophyx |
| Redhill Biopharma INC. | $27.57 | 2022 | |
| Genzyme Corporation | $25.40 | 2023 | |
| Mauna Kea Technologies, INC. | $24.08 | 2025 | |
| Ferring Pharmaceuticals INC. | $22.17 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.46 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.71 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.55 | 2021 | |
| Organon LLC | $11.47 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.